secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001193125-25-229231
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics transfers to Nasdaq Capital Market; extended bid price deadline to March 2026
--------------------------------------------------------------------------------

- Company received approval on Oct 2, 2025 to transfer listing from Nasdaq Global Select to Capital Market, effective Oct 6.
- Transfer follows failure to meet $1.00 minimum bid price requirement for continued Global Select listing.
- Nasdaq granted additional 180-day period until March 30, 2026 to regain compliance with minimum bid price.
- Stock must close at $1.00+ for 10 consecutive business days to regain compliance; company evaluating options.
- Common stock continues to trade under symbol XLO on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/0001193125-25-229231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/d74952d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-229231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer